HARVONI
Active Ingredient: SOFOSBUVIR, LEDIPASVIR
Product Overview
About HARVONI
HARVONI is a prescription medication containing the active ingredients Sofosbuvir and Ledipasvir. It is used to treat chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis and in patients with HCV genotype 1, 4, 5, or 6 infection without cirrhosis.
Key Benefits & Uses
- Treatment of chronic HCV genotype 1, 4, 5, or 6 infection in adults with compensated liver disease.
- Treatment of chronic HCV genotype 1 infection in adults without cirrhosis.
- Combination therapy with other medications to achieve a sustained virologic response (SVR) in patients with HCV infection.
Active Ingredient & Action
Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, while Ledipasvir is an inhibitor of the HCV NS5A protein. The combination of Sofosbuvir and Ledipasvir works by inhibiting the replication of the HCV virus, thereby reducing the viral load in the body and allowing the liver to recover.
Important Notes
HARVONI is available in tablet form and should be taken once daily with a meal. It is essential to follow the prescribed dosage and treatment duration to achieve optimal results. Patients with a history of liver disease or other medical conditions should consult their healthcare provider before starting treatment with HARVONI. Common side effects may include headache, fatigue, and nausea. It is crucial to discuss any concerns or questions with a healthcare provider before taking HARVONI.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
